Maturlo S J, Rosenbaum R L, Pan C, Surks M I
J Clin Invest. 1980 Sep;66(3):451-6. doi: 10.1172/JCI109875.
Although a normal serum thyrotropin (TSH) concentration is generally considered to be the most important finding to support the clinical impression of euthyroidism in patients with nonthyroidal diseases and decreased serum triiodothyronine (T(3)), the regulation of TSH secretion in sick patients has not been studied previously. Accordingly, we studied the regulation of TSH secretion in 23 patients with nonthyroidal diseases; 15 of the patients had decreased serum T(3). TSH regulation was studied by measuring the TSH response to injected thyrotropin-releasing hormone (TRH) before and after effecting a small decrease in serum thyroxine (T(4)) and/or T(3) concentrations by iodide treatment, 262 mg daily for 10 d. Iodide treatment significantly decreased (> 10%) the free T(4) index (FT(4)-I) and/or free T(3) index (FT(3)-I) in all patients. FT(4)-I values were correlated (0.611, P < 0.001), with free T(4) concentration determined by equilibrium dialysis. Despite decreased FT(4)-I and/or FT(3)-I after iodide treatment in all patients, the TSH response to TRH after iodide treatment was augmented in only 8 of 15 patients who had decreased serum T(3) (group 1) and in only 5 of 8 patients who had a normal serum T(3). Mean base-line TSH concentration was increased significantly (P < 0.05) from 0.9+/-0.1 to 1.5+/-0.3 muU/ml in group 1 only. Comparison of the mean TSH response to TRH showed that there was no significant difference between groups 1 and 2. Moreover, no significant difference in thyroidal parameters was observed between patients who had augmented TSH response to TRH after iodides and those who had either similar or decreased TSH response irrespective of the initial serum T(3). These studies show that an augmented TSH response to TRH in response to a small reduction in serum T(4) and T(3) concentration occurred in only 57% of the entire group of patients with nonthyroidal diseases and that the presence or absence of a normal TSH response to this stimulus did not seem to be related to the base-line serum T(3) concentration. Because an increase in serum TSH in response to decreased serum T(4) and T(3) did not occur in about one-half of patients with nonthyroidal diseases, normal serum TSH may not be a reliable index of the euthyroid state in these patients.
尽管正常血清促甲状腺激素(TSH)浓度通常被认为是支持非甲状腺疾病患者甲状腺功能正常临床印象以及血清三碘甲状腺原氨酸(T₃)降低的最重要发现,但此前尚未对患病患者TSH分泌的调节进行研究。因此,我们研究了23例非甲状腺疾病患者TSH分泌的调节情况;其中15例患者血清T₃降低。通过在每日服用262毫克碘化物,持续10天,使血清甲状腺素(T₄)和/或T₃浓度略有下降之前和之后,测量对注射促甲状腺激素释放激素(TRH)的TSH反应,来研究TSH调节。碘化物治疗使所有患者的游离T₄指数(FT₄-I)和/或游离T₃指数(FT₃-I)显著降低(>10%)。FT₄-I值与通过平衡透析测定的游离T₄浓度相关(0.611,P<0.001)。尽管所有患者在碘化物治疗后FT₄-I和/或FT₃-I降低,但在血清T₃降低的15例患者中,只有8例(第1组)以及血清T₃正常的8例患者中只有5例,碘化物治疗后对TRH的TSH反应增强。仅第1组的平均基线TSH浓度从0.9±0.1显著增加(P<0.05)至1.5±0.3 μU/ml。对TRH的平均TSH反应比较显示,第1组和第2组之间无显著差异。此外,无论初始血清T₃如何,碘化物后对TRH的TSH反应增强的患者与TSH反应相似或降低的患者之间,甲状腺参数均未观察到显著差异。这些研究表明,在整个非甲状腺疾病患者组中,仅57%的患者在血清T₄和T₃浓度略有降低时对TRH的TSH反应增强,并且对这种刺激的TSH反应正常与否似乎与基线血清T₃浓度无关。由于约一半的非甲状腺疾病患者在血清T₄和T₃降低时血清TSH并未升高,因此正常血清TSH可能不是这些患者甲状腺功能正常状态的可靠指标。